Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens

Biomarkers

Volumn 20, Issue 1, 2015, Pages 77-83

  Medrano, Alfonso Segarra ^a   Escalante, Elias Jatem ^a   Cáceres, Clara Carnicer ^a   Pamplona, Irene Agraz ^a   Allende, Maria Teresa Salcedo ^a   Terrades, Natalia Ramos ^a   Carmeno, Naiara Valtierra ^a   Roldán, Elena Ostos ^a   Agudelo, Karla Viviana Arredondo ^a   Vasquez, Juliana Jaramillo ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cyclophospamide; Membranous nephropathy; Renal disease; Rituximab; Type M phospholipase A2 antibodies

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; PHOSPHOLIPASE A2 RECEPTOR; PREDNISONE; RITUXIMAB; TACROLIMUS; AUTOANTIBODY; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; OUTCOME VARIABLE; PREDICTIVE VALUE; PROGNOSIS; PROTEINURIA; REMISSION; TREATMENT RESPONSE; BLOOD; GLOMERULONEPHRITIS, MEMBRANOUS; IMMUNOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AUTOANTIBODIES; BIOLOGICAL MARKERS; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, PHOSPHOLIPASE A2; TREATMENT OUTCOME;

EID: 84921729984     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2014.993708     Document Type: Article

References (26)

1. Bech AP, Hofstra JM, Brenchley PE, Wetzels JF. (2014). Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 9:1386-92.
2. Beck Jr LH, Bonegio RG, Lambeau G, et al. (2009). M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361:11-21.
3. Beck Jr LH, Fervenza FC, Beck DM, et al. (2011). Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22:1543-50.
4. Behnert A, Schiffer M, Müller-Deile J, et al. (2014). Antiphospholipase A2 receptor autoantibodies: a comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy. J Immunol Rs 143274. doi: 10.1155/2014/143274. Epub 2014 Apr 9. PubMed PMID: 24812637; PubMed Central PMCID: PMC4000632.
5. Caro J, Gutiérrez-Solís E, Rojas-Rivera J, et al.; for the Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN) (2014). Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus. Nephrol Dial Transplant; pii: gfu306 [Epub ahead of print].
6. Cattran DC, Appel GB, Hebert LA, et al.; North America Nephrotic Syndrome Study Group. (2001). Cyclosporine in patients with steroid resistant membranous nephropathy A randomized trial. Kidney Int 59: 1484-90.
7. Cattran DC, Greenwood C, Ritchie S, et al. (1995). A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Kidney Int 47:1130-5.
8. Donadio Jr JV, Holley KE, Andersons CF, Taylor WF. (1974). Controlled trial of cyclophosphamide in idiopathic membranous nephropathy. Kidney Int 6:431-9.
9. Donadio Jr JV, Torres VE, Velosa JA, et al. (1988). Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int 33:708-15.
10. Fulladosa X, Praga M, Segarra A, Martínez Ara J. (2007). Tratamiento del síndorme nefrótico primario. Glomerulonefritis membranosa. Nefrología 27:70-86.
11. 2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 6:1286-91.
12. Hofstra JM, Branten AJ, Wirtz JJ, et al. (2010). Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial. Nephrol Dial Transplant 25:129-36.
13. Hofstra JM, Fervenza FC, Wetzels JF. (2013). Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol 9:443-58.
14. Hofstra JM, Wetzels JF. (2012). Anti-PLA2R antibodies in membranous nephropathy: ready for routine clinical practice? Neth J Med 70: 109-13.
15. 2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 26:2526-32.
16. Hoxha E, Thiele I, Zahner G, et al. (2014). Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol 6:1357-66.
17. Jha V, Ganguli A, Saha TK, et al. (2007). A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 18: 1899-904.
18. Kanigicherla D, Gummadova J, McKenzie EA, et al. (2013). Anti- PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 83:940-8.
19. KDIGO Clinical Practice Guideline for Glomerulonephritis. (2012). Idiopathic membranous nephropathy. Kidney Int Suppl 2:186-97.
20. Kerjaschki D. (2004). Pathomechanisms and molecular basis of membranous glomerulopathy Lancet 364:1194-6.
21. Levey AS, Stevens LA, Schmid CH, et al. (2009). CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): a new equation to estimate glomerular filtration rate. Ann Intern Med 150:604-12.
22. Ponticelli C, Altieri p. Scolari F, et al. (1998). A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 9:444-50.
23. Praga M, Barrio V, Juárez GF, Luño J; Grupo Español de Estudio de la Nefropatía Membranosa. (2007). Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int 71: 924-30.
24. Qin W, Beck Jr LH, Zeng C, et al. (2011). Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 22: 1137-43.
25. Segarra-Medrano A, Jatem-Escalante E, Carnicer-Cáceres C, et al. (2014). Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus. Nefrologia 4:491-7.
26. van den Brand JA, van Dijk PR, Hofstra JM, Wetzels JF. (2014). Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. J Am Soc Nephrol 25: 150-8.